|
[Ceritinib in lung cancer] |
González L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Ceritinib in lung cancer] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 544. 2017 Authors' conclusions There is no evidence that the use of ceritinib increases overall survival in patients with advanced non-small cell lung cancer. Good quality evidence shows that its use, when compared with chemotherapy, would increase progression-free survival and overall response rate as first-line treatment or in patients who previously received crizotinib; being the first indication not approved by ANMAT (Argentina's National Administration of Medicaments, Food and Medical Technology) or other regulatory agencies yet. No studies assessing its efficacy and safety versus crizotinib or other treatment options have been found.
There is consensus among the clinical practice guidelines from main international societies on considering ceritinib among the treatment options in those patients with advanced ALK+ non-small cell lung cancer, who show progression after treatment with crizotinib or in case of intolerance to it. The coverage policies from public and private health sponsors consulted cover it for this indication, in some cases only after reaching an agreement on the selling price. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Humans; Lung Neoplasms; Pyrimidines; Sulfones Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000309 Date abstract record published 13/06/2017 |
|
|
|